Suppression of c-MET overcomes erlotinib resistance in tongue cancer cells

BACKGROUND: Erlotinib is a commonly used molecular-targeted drug for the treatment of tongue cancer. However, the development of acquired resistance to erlotinib hampers its therapeutic use. MATERIALS AND METHODS: To analyze the erlotinib resistance, long-term and short term survival assay were used...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Keqiang, Liu, Dongxu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134955/
https://www.ncbi.nlm.nih.gov/pubmed/30233210
http://dx.doi.org/10.2147/OTT.S167936

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134955/
https://www.ncbi.nlm.nih.gov/pubmed/30233210
http://dx.doi.org/10.2147/OTT.S167936

Ejemplares similares